SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Avidity Biosciences Inc (RNAM) , forward earnings yield 0.12%. PEG 0.12 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 857.2
- PEG Ratio 0.12 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Overall SharesGrow Score: 39/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RNAM
Valuation Multiples
P/E (TTM)0.0
Forward P/E857.2
PEG Ratio0.12
Forward PEG0.12
P/B Ratio0.00
P/S Ratio534.98
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-4.97
Forward EPS (Est.)$0.09
Book Value / Share$0.00
Revenue / Share$0.14
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield0.12%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.30 |
$379K |
$-11.22M |
-2959.4% |
| 2019 |
$-0.66 |
$2.32M |
$-24.73M |
-1066.6% |
| 2020 |
$-2.05 |
$6.79M |
$-44.36M |
-653.5% |
| 2021 |
$-2.85 |
$9.33M |
$-118.01M |
-1265.4% |
| 2022 |
$-3.34 |
$9.22M |
$-174M |
-1886.3% |
| 2023 |
$-2.91 |
$9.56M |
$-212.22M |
-2219.9% |
| 2024 |
$-2.89 |
$10.9M |
$-322.3M |
-2957.7% |
| 2025 |
$-4.97 |
$18.76M |
$-684.63M |
-3650.4% |
